How did INBS's revenue streams evolve in Q2 2025 compared to previous quarters?

Intelligent Bio Solutions Inc. (INBS) did not report any revenue in Q2 2025, Q1 2025, Q3 2024, or Q4 2023. However, it is important to note that the company has been actively expanding its global reach and language capabilities, which could potentially lead to revenue growth in future quarters.

1. **Global Expansion**: INBS has been driving global growth through multilingual digital expansion, launching websites in Arabic, Italian, and Spanish to unlock commercial access to regions representing over 1.4 billion people. This strategic move aligns with product readiness and accelerates international sales pipeline development.
2. **Product Enhancements**: The company has integrated Latin American Spanish into its Intelligent Fingerprinting Drug Screening System, enhancing its multilingual functionality and expanding accessibility across Spanish-speaking markets. This enhancement is part of a broader upgrade targeting over 4 billion speakers worldwide and is designed to support INBS' growing global footprint.
3. **Market Positioning**: INBS is positioning itself strategically to capitalize on the growing demand for drug screening solutions in the Latin American market, which is projected to reach $1.1 billion by 2030. The company's non-invasive testing solutions are in high demand, offering a portable and hygienic alternative to traditional urine or saliva testing.

While INBS did not report any revenue in the specified quarters, its strategic global expansion and product enhancements are likely to pave the way for revenue growth as these initiatives mature and contribute to the company's international sales pipeline.